Slides
Page 1
NASDAQ: PYPD Corporate Presentation November 2025
Page 2
2 This presentation of PolyPid Ltd. (the“Company”) contains“forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,”“plans,”“believes,”“seeks,”“estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses statements relating to our objectives, plans, and strategies, the expected timing of trials, the research, development, and use of our platform technologies, technologies, products and product candidates, potential benefits and advantages of our products and product candidates, and all statements (other than statements of historical facts) that address activities, events, or developments that the Company intends, expects, projects, believes, or anticipates will or may occur in the future, the safety, efficacy and benefits of D-PLEX100 and US addressable market. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F, filed with the SEC on February 26, 2025. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. Cautionary Note Regarding Forward Looking Statements
Page 3
3 PolyPid Overview HQs Global: Petach Tikva, Israel US: New Jersey 176 granted and pending patents (1) 74 employees(1) Polymer-Lipid Encapsulation matriX (PLEX) Platform Pre-NDA stage biopharma company Unique LOCAL Prolonged Delivery of APIs Lead Product D-PLEX100 in Phase 3 trial OncoPLEX Next Big Opportunity for Solid Tumors 1 As of November ‘25 NASDAQ: PYPD
Page 4
4
Page 5
5 Robust Pipeline with Multiple Near- and Longer-Term Inflection Points
Page 6
6 D-PLEX100 is a Potential First-in-class for the prevention of SSIs Indication: Prevention of abdominal incisional SSI Doxycycline (broad spectrum antibiotic) FDA 505(b)(2) regulatory pathway Administered directly into the surgical site for prolonged 30 days release ~12M Surgeries addressable market in US Abdominal 4.5M Gyn & Uro 2.5M Sternum 0.5M Orthopedic 5.0M ~12M procedures Breakthrough Therapy, Fast Track, and QIDP designations
Page 7
7
Page 8
8 Scope • Assess the efficacy and safety of D-PLEX100 in the prevention of post abdominal surgery incisional infection • Prospective, multinational, randomized, controlled, two- arm, double-blind study • Global trial, ~60 sites in US, Europe, and Israel Patient Population • Patients undergoing elective abdominal colorectal surgery with incision length > 20 cm • ITT cohort: 798 patients • Randomization 1:1 30 600 D-PLEX100 + SOC (N=405) SOC (N=393) Primary efficacy endpoint assessment within 30 days post index surgery Safety assessment at 60 days post index surgery
Page 9
9 SHIELD II Demographics & Surgery Characteristics (ITT Cohort) Parameter D-PLEX100 (N=405) SoC (N=393) Age (yrs) 67.0 68.0 Female (%) 44.0% 37.9% BMI (Kg/m2) 26.2 26.4 Charlson co-morbidity index 4.0 5.0 Surgery duration (hrs) 2.4 2.3 Indication for index surgery (%) Cancer 86.2% 91.1% Inflammatory Bowel Disease (IBD) 2.0% 0.3% Other 11.9% 8.7% Preoperative IV antibiotics given prior to index surgery (%) 100% 99.5%
Page 10
10 D-PLEX100 Showed Statistically Significant Reduction in the Primary Efficacy Endpoint * SoC - Standard of Care 71 44 SoC * D-PLEX100 + SOC n=393 n=405 (10.9%) (18.1%) 38% reduction (p<0.005) D-PLEX100 + SoC Primary Efficacy Endpoint (ITT cohort)
Page 11
11 36 15 SoC * D-PLEX100 + SOC Surgical Site Infection (SSI) (ITT Cohort) Key Secondary Efficacy Endpoint #1 * SoC - Standard of Care n=377 n=391 (3.8%) (9.5%) 58% reduction (p<0.005) D-PLEX100 + SoC Surgical Site Infection rate – intention to treat population: At least one abdominal incisional surgical site infection event, occurring within 30 days post abdominal (index) surgery in the population of subjects with incision length >20 cm (n=798 patients)
Page 12
12 Key Secondary Efficacy Endpoint #2 * SoC - Standard of Care Combined Efficacy Endpoint - overall study population: A combination of at least one SSI event in the overall study population of subjects with incision length >7 cm (n=975 patients), all-cause mortality and re-interventions through the abdominal incision within 30 days post index surgery 85 54 SoC * D-PLEX100 + SOC n=488 n=487 (11.1%) (17.4%) 36% reduction (p<0.005) D-PLEX100 + SoC Combined Efficacy Endpoint (Overall Study Population)
Page 13
13 Key Secondary Efficacy Endpoint #3 * SoC - Standard of Care ASEPSIS Score – ITT Cohort: Number of subjects with ASEPSIS score >20 within 30 days post abdominal (index) surgery. The ASEPSIS score is a clinical tool used to objectively assess surgical wound infections. 21 8 SoC * D-PLEX100 + SOC n=377 n=391 (2.0%) (5.6%) 62% reduction (p<0.05) D-PLEX100 + SoC ASEPSIS Score >20 (ITT Cohort)
Page 14
14 Target Market at Launch is >7M Surgeries in US & Europe* * Assuming additional safety and PK Study for US ; Expected Abdominal Indication in Europe based on SHIELD 2 phase 3 trial **Source IQVIA PM&I Global FlexView. Internal analysis 8M Europe total addressable market in-patient surgical procedure 12M US total addressable market in-patient surgical procedures 3M Abdominal Surgeries 4.4M Abdominal Surgeries 7,400K** Core Target Surg. Procedures
Page 15
Demonstrated Economic Benefits will be Essential for Market Access and Sales Uptake D-PLEX100 is eligible for NTAP program up to 75% reimbursement of cost of drug 15 Direct cost SSI costs ~$25K/patient1 on average • Prolonged length of stay and higher readmission rates • Re-operation in some cases (to debride and remove infected / necrotic tissues) Reputational cost Hospital SSI rates are public information and have direct influence on hospital ranking by CMS and U.S. News best hospitals ranking Indirect cost CMS 1-3% penalty on all the yearly Hospital Medicare reimbursement 1. Stone PW. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):417-22.
Page 16
16 Market Access Study Findings: Surgeon Point-of-View Surgeons perceived D-PLEX100 to be highly valuable for SSI prevention, more valuable overall than currently used interventions Surgeons are very likely to use D-PLEX100 if on formulary and stocked – likely used in 6 out of 10 patients Most Mentioned Patients Appropriate for D-PLEX100 Any patient with a higher risk of infection – immunocompromised, comorbidities, obese, uncontrolled diabetics, transplant patients Patients undergoing Colorectal Surgeries Any procedure with incisions >10 cm Source: Indegene Market Research October 2025 10% 40% 80% 20% 10% 40% 20% 80% 80% 20% Unaided F / S F / NS NF / NS Extremely likely likely Not at all likely F/S – On Formulary & Stocked; F/NS = On Formulary, but NOT Stocked; NF/NS = Not on Formulary & Not Stocked How likely are you to prescribe Product X to prevent SSIs in eligible surgical patients? (% of responders)
Page 17
17 Market Access Study Findings: Pharmacy Directors Point-of-View D-PLEX100 is viewed as a promising SSI prevention agent due to its strong efficacy, localized action, and safety Value perception and likelihood for formulary coverage and stocking are high and grow even higher with the introduction of NTAPANTICIPATED REVIEW PROCESS Reviewed by the P&T committee on clinical benefits, logistical needs, and cost Multi-disciplinary assessment with inputs from infectious disease specialists, surgeons, and finance (contracting) Pilot studies may be run to assess utility and volume Final formulary and access decisions by the P&T committee May add to formulary with restrictions based on anticipated clinical benefits, use (volume), cost, and potential cost offsets 30% 10% 10% 70% 90% 90% Value Rating Likelihood for Formulary Coverage Likelihood for Stocking Extremely likely likely How valuable do you perceive Product X to be on a 1 to 10 scale? (% of Responders) Source: Indegene Market Research October 2025
Page 18
18 Global Go-to-market Strategy *Announced August 3rd, 2022 Next-in-line US, Canada, China and South America Agreement highlights Partnerships with leading pharma companies with established hospital-focused commercial capabilities and resources Includes European Economic Area and UK Potentially receive over $115 million in upfront and milestone payments as well as royalties on net sales $2.7 million upfront payment paid upon signature of licensing agreement Focused on abdominal and cardiac indications Development-related milestones for a total of up to $25 million Signed licensing agreement includes transfer price, development and sales-related milestone payments and royalties Next-in-line Partnered territories w/ Advanz Pharma
Page 19
19 State-of-the-Art Manufacturing Facility PolyPid was granted Manufacturer Authorization and Good Manufacturing Practice – GMP - certification by Israel’s MoH and EU qualified person for its state-of-the-art ~18,000 square feet (~1,700 m2) manufacturing facility. Investment machinery, qualifications and validations Supply capacity expected to meet commercial demand for the first 4-5 years from launch
Page 20
20 R&D Collaboration Agreement with Immunogenesis for Controlled and Prolonged Intratumoral Delivery • Houston-based company founded by Dr. Michael Curran, Associate Professor of Immunology at the MD Anderson Cancer Center • Combined Immunogenesis potent anti-tumor STING agonist with PolyPid’s technology to enhance treatment for solid tumors • Aim to overcome shortcoming of STING agonists molecules, which are susceptible to rapid clearance
Page 21
25 Financials Top Holders Analyst coverage Brandon Folkes 1. As of November 12, 2025 2.As of September 30, 2025 Stock Information Listing NASDAQ Ticker PYPD 52-week range1 $2.30-$3.93 Market cap1 $77 M Share Structure2 Shares outstanding 16.6 M Pre-funded warrants and shares held in abeyance 3.6M Warrants 1.7 M @ $3.61 exercise price Warrants 7.6 M @ $4.50 exercise price Warrants 1.2 M @ $5.50 exercise price Options outstanding 2.9 M @ $4.82 WAEP Chase Knickerbocker Boobalan Pachaiyappan
Page 22
Key Accomplishments Reached primary and all key secondary endpoints in D-PLEX100 Phase 3 trial Completed process validation for D-PLEX100 and passed cGMP inspection – manufacturing facility ready for EU launch Completed the largest Phase 3 trial in prevention of SSI in colorectal resection in over a decade Signed a commercialization agreement for Europe - deal worth >$110 million in milestone payments plus royalties and transfer price Advanced the development of OncoPLEX including pre-IND studies Sufficient cash well into 2026
Page 23
THANK YOU Polypid.com